Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
IJB-REGINA-2020
The George Institute
Locally-advanced stage II-III rectal cancer
1 trial -
IJB-SYNERGY-012017
The George Institute
Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
1 trial -
IJB-ZEPHIR02-2024
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
IJB-ZEPHIR02-2024
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
IKF/AIO-ZANGEA
The George Institute
Gastroesophageal Adenocarcinoma
1 trial -
IMC-R117C
Immunocore Ireland Limited
Cancer
1 trial -
IMCgp100-202
Immunocore Ireland Limited
Previously untreated advanced uveal melanoma (UM)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
CERO THERAPEUTICS HOLDINGS, INC.
Non small cell lung cancer, Poor general status
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
Fondazione Telethon ETS
NSCLC non-small cell lung cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
Ningbo Cancer Hospital
Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
CERO THERAPEUTICS HOLDINGS, INC.
oligometastatic hormone sensitive prostate cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
The George Institute
unresectable stage III NSCLC (Non–small-cell lung cancer)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
The George Institute
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Patients With Muscle-Invasive Bladder Cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
Ningbo Cancer Hospital
Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
Ningbo Cancer Hospital
Muscle-invasive bladder cancer
1 trial -
IMFINZI for Metastatic pancreatic cancer
Disc Medicine
Metastatic pancreatic cancer
1 trial -
IMGN151-1001
AbbVie Deutschland GmbH & Co. KG
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer
1 trial -
IMGN632-0802
AbbVie Deutschland GmbH & Co. KG
CD123 positive Acute Myeloid Leukemia
1 trial -
IMGN853-0424
AbbVie Deutschland GmbH & Co. KG
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
1 trial -
IMMU-132-06
Gilead Sciences Pty Limited
Locally Advanced/Metastatic Urothelial Cancer
1 trial -
IMMUWHY
The George Institute
Advanced stage intrahepatic biliary tract cancer (BTC)
1 trial -
IMMUWIN
The George Institute
Intermediate stage hepatocellular carcinoma (HCC)
1 trial -
IMP1734
Eikon Therapeutics
Advanced Solid Tumor
1 trial -
IMX-110 combined with Tislelizumab
Immix Biopharma
Advanced Solid Tumor
1 trial -
IN10018
Hospital Authority, Hong Kong
Cervical Adenocarcinoma
1 trial -
INAVOLISIB
Fondazione Telethon ETS
endometrial cancer
1 trial -
INBRX-106 - Hexavalent OX40 agonist antibody
Inhibrx Biosciences
Solid Tumor
1 trial -
INBRX-109
Inhibrx Biosciences
Conventional Chondrosarcoma
1 trial -
INC280
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
INCB 84344-102
Incyte
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
1 trial -
INCB099280, Adagrasib
Incyte
Advanced Solid Tumors Harboring a KRASG12C Mutation
1 trial -
INCB123667-203
Incyte
Ovarian Cancer
1 trial -
INCMGA0012-204
Incyte
Endometrial cancer, Endometrial cancer
1 trial -
INDOCYANINE GREEN
The George Institute
Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery
1 trial -
INDOCYANINE GREEN
Fondazione Telethon ETS
Patients with gynecological cancers undergoing pelvic exenteration
1 trial -
INES
Fondazione Telethon ETS
Ewing Sarcoma
1 trial -
INO-3112
INOVIO PHARMACEUTICALS, INC.
Head and Neck Squamous Cell Cancer
1 trial -
INO-3112
INOVIO PHARMACEUTICALS, INC.
Cervical Cancer
1 trial -
INO-3112 vaccine
INOVIO PHARMACEUTICALS, INC.
Uterine Cervical Neoplasms
1 trial -
INO-5401
INOVIO PHARMACEUTICALS, INC.
Urothelial Carcinoma
1 trial -
INT230-6
INTENSITY THERAPEUTICS, INC.
Breast Cancer
2 trials -
INXN-2001
Alaunos Therapeutics
Melanoma
1 trial -
IO102-IO103
IO Biotech
Melanoma
2 trials -
IO102-IO103 in combination with pembrolizumab
IO Biotech
Lung Cancer Non Small Cell
1 trial -
IOB-022/KN-D38
IO Biotech
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
IONIS-STAT3Rx
IONIS PHARMACEUTICALS INC
Advanced Cancers
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.